Juno Therapeutics

Activities: Research & Development

Trending Articles

  1. Johnson & Johnson to invest $55bn into US manufacturing, R&D and tech The company will build three new advanced pharmaceutical manufacturing facilities on top of its biologics manufacturing site in Wilson, North Carolina, which is currently under...
  2. Maximising efficiency in sample preparation with miVac Sample evaporation and concentration are critical steps in many R&D workflows, but inefficiencies can slow processes and impact results
  3. AstraZeneca puts $2.5bn into Chinese R&D and manufacturing capabilities The pharmaceutical giant will establish its sixth strategic R&D centre in China, as well as novel research and manufacturing agreements in the region
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Forecasting the future of peptide manufacturing: CMC challenges in the GLP-1 era In this article, Torsten Wöhr, Chief Commercial Officer at Bachem, explores the future of peptide CMC manufacturing for GLP-1 therapies, including innovations in sustainable...
  5. Korean certification for portable VOC emissions analyser Signal Group’s portable VOC analyser, the 3010 MiniFID has achieved NIER certification, demonstrating compliance with Article 9 of South Korea’s Environmental Testing and...

Upcoming event

Interphex

1–3 April 2025 | Conference and Exhibition | New York, US See all

Related Content

Media

Celgene set to become leader in CAR-T space

According to GlobalData, a data and analytics company, Celgene’s acquisition of Juno Therapeutics puts the company in a good position to be a frontrunner in the chimeric antigen receptor-T cell space
Research & Development

Juno Therapeutics and WuXi AppTec announce new company to develop novel cell-based cancer immunotherapies in China

JW Biotechnology will Leverage Juno's immuno-oncology expertise and assets and WuXi AppTec's R&D and manufacturing platform
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Homing in on cancer targets

Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach
Finance

Juno Therapeutics acquires German biotech Stage Cell Therapeutics for US$81m

Gaining access to transformative cell selection and activation capabilities
Research & Development

US cancer research centres launch biotech start-up

Juno Therapeutics will have US$120m initial investment and develop cancer immunotherapy products
Subscribe now